Therapeutic targets in necrotizing soft tissue infections

go back to reference Das DK, Baker MG, Venugopal K (2012) Risk factors, microbiological findings and outcomes of necrotizing fasciitis in New Zealand: a retrospective chart review. BMC Infect Dis 12:348CrossRefPubMedPubMedCentral Das DK, Baker MG, Venugopal K (2012) Risk factors, microbiological findings and outcomes of necrotizing fasciitis in New Zealand: a retrospective chart review. BMC Infect Dis 12:348CrossRefPubMedPubMedCentral

go back to reference Hua C, Sbidian E, Hemery F, Decousser JW, Bosc R, Amathieu R, Rahmouni A, Wolkenstein P, Valeyrie-Allanore L, Brun-Buisson C, de Prost N, Chosidow O (2015) Prognostic factors in necrotizing soft-tissue infections (NSTI): a cohort study. J Am Acad Dermatol 73(1006–1012):e1008 Hua C, Sbidian E, Hemery F, Decousser JW, Bosc R, Amathieu R, Rahmouni A, Wolkenstein P, Valeyrie-Allanore L, Brun-Buisson C, de Prost N, Chosidow O (2015) Prognostic factors in necrotizing soft-tissue infections (NSTI): a cohort study. J Am Acad Dermatol 73(1006–1012):e1008

go back to reference Swartz MN (2004) Clinical practice. Cellulitis. N Engl J Med 350:904–912CrossRefPubMed Swartz MN (2004) Clinical practice. Cellulitis. N Engl J Med 350:904–912CrossRefPubMed

go back to reference Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP (2017) Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377CrossRefPubMed Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP (2017) Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377CrossRefPubMed

go back to reference Perner A, Gordon AC, De Backer D, Dimopoulos G, Russell JA, Lipman J, Jensen JU, Myburgh J, Singer M, Bellomo R, Walsh T (2016) Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Med 42:1958–1969CrossRefPubMed Perner A, Gordon AC, De Backer D, Dimopoulos G, Russell JA, Lipman J, Jensen JU, Myburgh J, Singer M, Bellomo R, Walsh T (2016) Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Med 42:1958–1969CrossRefPubMed

go back to reference Pham TN, Moore ML, Costa BA, Cuschieri J, Klein MB (2009) Assessment of functional limitation after necrotizing soft tissue infection. J Burn Care Res 30:301–306CrossRefPubMedPubMedCentral Pham TN, Moore ML, Costa BA, Cuschieri J, Klein MB (2009) Assessment of functional limitation after necrotizing soft tissue infection. J Burn Care Res 30:301–306CrossRefPubMedPubMedCentral

go back to reference Elliott DC, Kufera JA, Myers RA (1996) Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann Surg 224:672–683CrossRefPubMedPubMedCentral Elliott DC, Kufera JA, Myers RA (1996) Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann Surg 224:672–683CrossRefPubMedPubMedCentral

go back to reference Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC (2014) Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 59:e10–52CrossRefPubMed Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC (2014) Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 59:e10–52CrossRefPubMed

go back to reference Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R (2014) Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis 59:358–365CrossRefPubMed Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R (2014) Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis 59:358–365CrossRefPubMed

go back to reference de Prost N, Sbidian E, Chosidow O, Brun-Buisson C, Amathieu R, Henri Mondor Hospital Necrotizing Fasciitis Group (2015) Management of necrotizing soft tissue infections in the intensive care unit: results of an international survey. Intensive Care Med 41:1506–1508CrossRefPubMed de Prost N, Sbidian E, Chosidow O, Brun-Buisson C, Amathieu R, Henri Mondor Hospital Necrotizing Fasciitis Group (2015) Management of necrotizing soft tissue infections in the intensive care unit: results of an international survey. Intensive Care Med 41:1506–1508CrossRefPubMed

go back to reference Kadri SS, Swihart BJ, Bonne SL, Hohmann SF, Hennessy LV, Louras P, Evans HL, Rhee C, Suffredini AF, Hooper DC, Follmann DA, Bulger EM, Danner RL (2017) Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor-dependent shock: a propensity score-matched analysis from 130 US hospitals. Clin Infect Dis 64:877–885PubMed Kadri SS, Swihart BJ, Bonne SL, Hohmann SF, Hennessy LV, Louras P, Evans HL, Rhee C, Suffredini AF, Hooper DC, Follmann DA, Bulger EM, Danner RL (2017) Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor-dependent shock: a propensity score-matched analysis from 130 US hospitals. Clin Infect Dis 64:877–885PubMed

go back to reference Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O’Rourke K, Talbot J, Low DE (1999) Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 28:800–807CrossRefPubMed Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O’Rourke K, Talbot J, Low DE (1999) Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 28:800–807CrossRefPubMed

go back to reference Linner A, Darenberg J, Sjolin J, Henriques-Normark B, Norrby-Teglund A (2014) Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 59:851–857CrossRefPubMed Linner A, Darenberg J, Sjolin J, Henriques-Normark B, Norrby-Teglund A (2014) Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 59:851–857CrossRefPubMed

go back to reference Shah SS, Hall M, Srivastava R, Subramony A, Levin JE (2009) Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis 49:1369–1376CrossRefPubMedPubMedCentral Shah SS, Hall M, Srivastava R, Subramony A, Levin JE (2009) Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis 49:1369–1376CrossRefPubMedPubMedCentral

go back to reference Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglund A, Streptig Study Group (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37:333–340CrossRefPubMed Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglund A, Streptig Study Group (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37:333–340CrossRefPubMed

go back to reference Madsen M, Hjortrup P, Hansen M, Lange T, Norrby-Teglund A, Hyldegaard O, Perner A (2017) Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. Intensive Care Med. doi:10.1007/s00134-017-4786-0 Madsen M, Hjortrup P, Hansen M, Lange T, Norrby-Teglund A, Hyldegaard O, Perner A (2017) Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. Intensive Care Med. doi:10.​1007/​s00134-017-4786-0